Jump to content

MDFEM

From Wikipedia, the free encyclopedia

MDFEM
Clinical data
Other names4-(2,2-Difluoroethoxy)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2-difluoroethoxy)amphetamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • 1-[4-(2,2-difluoroethoxy)-2,5-dimethoxyphenyl]propan-2-amine
Chemical and physical data
FormulaC13H19F2NO3
Molar mass275.296 g·mol−1
3D model (JSmol)
  • CC(N)CC1=CC(OC)=C(OCC(F)F)C=C1OC
  • InChI=1S/C13H19F2NO3/c1-8(16)4-9-5-11(18-3)12(6-10(9)17-2)19-7-13(14)15/h5-6,8,13H,4,7,16H2,1-3H3
  • Key:AXKORAKXKXDBAF-UHFFFAOYSA-N

MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended.[1][2][3] The properties and effects of MDFEM in humans appear to be unknown.[1][2][3] The drug is a partial agonist of the serotonin 5-HT2A and 5-HT2B receptors and also shows other receptor interactions.[3] MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.[1][2][3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. 1 2 3 4 Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  3. 1 2 3 4 5 Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Frontiers in Pharmacology. 10 1423. doi:10.3389/fphar.2019.01423. PMC 6893898. PMID 31849671.
[edit]